In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases
The most important dose-limiting factor of the anthracycline idarubicin is the high risk of cardiotoxicity, in which the secondary alcohol metabolite idarubicinol plays an important role. It is not yet clear which enzymes are most important for the formation of idarubicinol and which inhibitors migh...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 January 2024
|
| In: |
Archives of toxicology
Year: 2024, Jahrgang: 98, Heft: 3, Pages: 807-820 |
| ISSN: | 1432-0738 |
| DOI: | 10.1007/s00204-023-03661-7 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00204-023-03661-7
|
| Verfasserangaben: | Gzona Bajraktari-Sylejmani, Julia Sophie Oster, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1884074286 | ||
| 003 | DE-627 | ||
| 005 | 20240703155912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00204-023-03661-7 |2 doi | |
| 035 | |a (DE-627)1884074286 | ||
| 035 | |a (DE-599)KXP1884074286 | ||
| 035 | |a (OCoLC)1443657782 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bajraktari-Sylejmani, Gzona |e VerfasserIn |0 (DE-588)1152395823 |0 (DE-627)1013994760 |0 (DE-576)499867106 |4 aut | |
| 245 | 1 | 0 | |a In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases |c Gzona Bajraktari-Sylejmani, Julia Sophie Oster, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss |
| 264 | 1 | |c 4 January 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.03.2024 | ||
| 520 | |a The most important dose-limiting factor of the anthracycline idarubicin is the high risk of cardiotoxicity, in which the secondary alcohol metabolite idarubicinol plays an important role. It is not yet clear which enzymes are most important for the formation of idarubicinol and which inhibitors might be suitable to suppress this metabolic step and thus would be promising concomitant drugs to reduce idarubicin-associated cardiotoxicity. We, therefore, established and validated a mass spectrometry method for intracellular quantification of idarubicin and idarubicinol and investigated idarubicinol formation in different cell lines and its inhibition by known inhibitors of the aldo-keto reductases AKR1A1, AKR1B1, and AKR1C3 and the carbonyl reductases CBR1/3. The enzyme expression pattern differed among the cell lines with dominant expression of CBR1/3 in HEK293 and MCF-7 and very high expression of AKR1C3 in HepG2 cells. In HEK293 and MCF-7 cells, menadione was the most potent inhibitor (IC50 = 1.6 and 9.8 µM), while in HepG2 cells, ranirestat was most potent (IC50 = 0.4 µM), suggesting that ranirestat is not a selective AKR1B1 inhibitor, but also an AKR1C3 inhibitor. Over-expression of AKR1C3 verified the importance of AKR1C3 for idarubicinol formation and showed that ranirestat is also a potent inhibitor of this enzyme. Taken together, our study underlines the importance of AKR1C3 and CBR1 for the reduction of idarubicin and identifies potent inhibitors of metabolic formation of the cardiotoxic idarubicinol, which should now be tested in vivo to evaluate whether such combinations can increase the cardiac safety of idarubicin therapies while preserving its efficacy. | ||
| 650 | 4 | |a 2′-hydroxyflavanone | |
| 650 | 4 | |a AKR | |
| 650 | 4 | |a CBR | |
| 650 | 4 | |a Idarubicin | |
| 650 | 4 | |a Idarubicinol | |
| 650 | 4 | |a Luteolin | |
| 650 | 4 | |a Menadione | |
| 650 | 4 | |a Ranirestat | |
| 700 | 1 | |a Oster, Julia Sophie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burhenne, Jürgen |d 1963- |e VerfasserIn |0 (DE-588)1034228889 |0 (DE-627)745126987 |0 (DE-576)381858197 |4 aut | |
| 700 | 1 | |a Haefeli, Walter E. |d 1958- |e VerfasserIn |0 (DE-588)124572359 |0 (DE-627)656806141 |0 (DE-576)340514221 |4 aut | |
| 700 | 1 | |a Sauter, Max |e VerfasserIn |0 (DE-588)1103516507 |0 (DE-627)86126813X |0 (DE-576)470642033 |4 aut | |
| 700 | 1 | |a Weiß, Johanna |e VerfasserIn |0 (DE-588)1050230906 |0 (DE-627)783666322 |0 (DE-576)404441114 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of toxicology |d Berlin : Springer, 1974 |g 98(2024), 3, Seite 807-820 |h Online-Ressource |w (DE-627)25339015X |w (DE-600)1458459-1 |w (DE-576)072283319 |x 1432-0738 |7 nnas |a In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases |
| 773 | 1 | 8 | |g volume:98 |g year:2024 |g number:3 |g pages:807-820 |g extent:14 |a In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00204-023-03661-7 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240322 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1050230906 |a Weiß, Johanna |m 1050230906:Weiß, Johanna |d 910000 |d 910100 |d 50000 |e 910000PW1050230906 |e 910100PW1050230906 |e 50000PW1050230906 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 6 |y j | ||
| 998 | |g 1103516507 |a Sauter, Max |m 1103516507:Sauter, Max |d 910000 |d 910100 |e 910000PS1103516507 |e 910100PS1103516507 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 124572359 |a Haefeli, Walter E. |m 124572359:Haefeli, Walter E. |d 910000 |d 910100 |e 910000PH124572359 |e 910100PH124572359 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1034228889 |a Burhenne, Jürgen |m 1034228889:Burhenne, Jürgen |d 910000 |d 910100 |e 910000PB1034228889 |e 910100PB1034228889 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1152395823 |a Bajraktari-Sylejmani, Gzona |m 1152395823:Bajraktari-Sylejmani, Gzona |d 910000 |d 910100 |e 910000PB1152395823 |e 910100PB1152395823 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1884074286 |e 4502983497 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1884074286","note":["Gesehen am 22.03.2024"],"relHost":[{"disp":"In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductasesArchives of toxicology","language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1974","publisher":"Springer","dateIssuedDisp":"1974-"}],"name":{"displayForm":["ed. on behalf of the Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie"]},"title":[{"subtitle":"official journal of EUROTOX","title":"Archives of toxicology","title_sort":"Archives of toxicology"}],"id":{"eki":["25339015X"],"zdb":["1458459-1"],"issn":["1432-0738"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["Volume 32, issue 1 (March 1974)-"],"note":["Gesehen am 11.08.25"],"part":{"text":"98(2024), 3, Seite 807-820","extent":"14","year":"2024","pages":"807-820","volume":"98","issue":"3"},"recId":"25339015X"}],"name":{"displayForm":["Gzona Bajraktari-Sylejmani, Julia Sophie Oster, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss"]},"id":{"eki":["1884074286"],"doi":["10.1007/s00204-023-03661-7"]},"physDesc":[{"noteIll":"Illustrationen","extent":"14 S."}],"origin":[{"dateIssuedDisp":"4 January 2024","dateIssuedKey":"2024"}],"language":["eng"],"person":[{"family":"Bajraktari-Sylejmani","given":"Gzona","roleDisplay":"VerfasserIn","role":"aut","display":"Bajraktari-Sylejmani, Gzona"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Julia Sophie","display":"Oster, Julia Sophie","family":"Oster"},{"family":"Burhenne","display":"Burhenne, Jürgen","given":"Jürgen","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Haefeli, Walter E.","roleDisplay":"VerfasserIn","role":"aut","given":"Walter E.","family":"Haefeli"},{"family":"Sauter","display":"Sauter, Max","given":"Max","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Weiß","display":"Weiß, Johanna","role":"aut","roleDisplay":"VerfasserIn","given":"Johanna"}],"title":[{"title":"In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases","title_sort":"In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases"}]} | ||
| SRT | |a BAJRAKTARIINVITROEVA4202 | ||